Member Info for Soupdragon78

Mars, who determines what path to take with NXP004?

Wacca, I wish we even had straws to try and clutch.

Still odd that Dan was labelled a ‘co-founder’ of TRx, yet he wasn’t listed as a director on the Class B allotment as it was mid May.

Likelihood that this is not NFX related, but you never know.

Also remember that the main force behind TRx (Bannister) was business partner of Julian Gilbert.

They’ve issued Class B shares which allow management to retain control whilst selling ordinary class A’s. This allows them to raise money without risk to control.

TRX Biosciences issuing more share out today, dunno why or what for yet.

Ok so no evidence then.

"There is NO evidence - none - to suggest that higher solubility will lead to materially higher efficacy at lower dose leading to materially lower side effects with this drug in this indication"

...

"pERC noted the Clinical Guidance Panel (CGP)’s conclusion that the bioavailability of the olaparib tablet appears to be greater due to improved solubility compared to the capsule and that the tablet dosage was better tolerated than higher dosages showing similar effectiveness in tumour shrinkage."

https://www.cadth.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_fn_rec.pdf

Ok Mulder, give me a link to your statement that there is no evidence solubility and efficacy.

Wonder why foremagnus stopped posting?

NLRP3 has become an attractive target in the drug discovery field and inhibitors possess high therapeutic value for the treatment of many diseases.

https://www.frontiersin.org/articles/10.3389/fnagi.2022.879021/full

Schrodingers TR1, they have both sold and not sold and we don't know until we know.

Hence its a pointless argument.

At the end of the day nobody posting on here knows the situation within the company, or the mindset of JH / DG etc.
it’s a binary situation, either you think things will improve in the future or you don’t.

There was a 9.4m sell for 0.4p on the Tuesday afternoon which was after his resignation.

But on the flip side there was a 2.5m & a 1.2m buy at 0.5 just before, and a further 7m in total clear cut buys as well on that same day.

Agree FX, just running through situations in my head really. Was thinking of the sequence of events and why the RNS for resignation was the day after when there is no reason for it not to have been on the same day as the Corporate Update.

The only two options I can think apply are that either he is really vindictive and wanted to hit the company hard (but why?) or that he didn't plan to resign and something happened on the Monday after the update.

On another note it’s good to see AR on LinkedIn thanking a recruitment consultant for playing a ‘very big part’ in his moved to Small Pharma.

What’s the bets that they were the same recruitment company he used to try and find a CEO but then ended up getting himself a new role.

Understandable concerns FX.

By way of looking at things from a different devils advocate perspective, we know AR was appointed by Small Pharma in the week before the corporate update, so he was defo aware of his circumstance.

Is it possible that he was aiming to stay at NFX, but the corporate update was badly received that major shareholders (DG, JH and Lanstead) gave him an ultimatum that day?

Hence his resignation was the day after.

The key short term issue is the wording around the NXP004 update.

“NXP004

The Company has previously demonstrated the enhanced performance of NXP004 compared to olaparib's free form. Subsequently, additional pre-formulation studies have been completed confirming the superiority of the Company's recently patented cocrystal forms and a lead cocrystal has been selected to enter drug product development. Further updates will be announced in due course.”

‘Previously demonstrated…’ does this refer to the testing that informed the Nov patent submission?

‘Subsequently, additional pre-formulation studies have been completed confirming the superiority…’

If these additional pre-formulation studies were undertaken subsequent to the Nov announcement, then these should really be talked about more.

‘a lead cocrystal has been selected to enter drug development…’

What is the timeline and strategy for this? Who will be undertaking it?

'Given that Nuformix and its development advisers believe that no positive or negative conclusions can be drawn from this study, the company, in consultation with the CRO, decided to move forward with further studies, including evaluation of a new inhaled formulation of NXP002.

The new studies will examine both the pharmacokinetics and effectiveness of this new formulation, and results are expected on or before the first months of next year, depending on the CRO’s availability.'

https://pulmonaryfibrosisnews.com/2022/06/07/inconsistent-results-delay-move-trials-ipf-therapy-nxp002/

FX, Its more trying to figure out what it is Oxilio are getting from LSHS?

The patent has both an inventor and an assignee.

Obviously the inventor is the name person or persons who came up with it. The assignee is the person or company who has the rights to the invention/patent.

If you are working on your own in your garden shed and come up with the cure for cancer, then you are both the inventor and by default the assignee.

If a scientist works for a company, then typically it is within their employment contract that any invention they work on / create during that employment, is assigned to the company.

Hence the NXP001 patent has DG as inventor (alongside JH, Chorlton and Frampton) but the patent is assigned to Nuformix, therefore NFX has the legal rights to the patent.
It is then licensed to Oxilio, but this doesn't show as its still owned by NFX, they just allow Oxilio to use it for recompense.

The thing I'm trying to figure is that Oxilio said that they were acquiring LSHS to gain IP related to NXP001. But given that the patents are assigned to NFX, I can't figure what that would be.

Filter, lots of things get said, the half years in December had AR saying

‘The new positive data sets on NXP002, patent progress on NXP004 and the licensing deal for NXP001 form the basis for further value creation in the next 12 months.’

Wonder if his ‘value creation’ strategy included walking?

NFT it’s almost as if Lanstead would benefit from the lower share price for another 7 months meaning they pay less for their holding.
Although Riddell did say this type of subscription wasn’t common, he’d only done it once before with Stanfords when he was Chair of Feedback.